It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
QSI’s FA Score shows that 0 FA rating(s) are green whileSLXN’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
QSI’s TA Score shows that 5 TA indicator(s) are bullish while SLXN’s TA Score has 4 bullish TA indicator(s).
QSI (@Biotechnology) experienced а -0.57% price change this week, while SLXN (@Biotechnology) price change was -10.07% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.32%. For the same industry, the average monthly price growth was +13.75%, and the average quarterly price growth was +8.90%.
QSI is expected to report earnings on Aug 11, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
QSI | SLXN | QSI / SLXN | |
Capitalization | 321M | 7.75M | 4,140% |
EBITDA | -105.87M | -16.96M | 624% |
Gain YTD | -35.185 | -59.204 | 59% |
P/E Ratio | N/A | N/A | - |
Revenue | 3.44M | 0 | - |
Total Cash | 233M | 6.15M | 3,787% |
Total Debt | 12.1M | 3.48M | 348% |
QSI | SLXN | |
---|---|---|
RSI ODDS (%) | 2 days ago90% | 2 days ago60% |
Stochastic ODDS (%) | 2 days ago90% | 2 days ago35% |
Momentum ODDS (%) | 2 days ago73% | 2 days ago17% |
MACD ODDS (%) | 2 days ago90% | 2 days ago15% |
TrendWeek ODDS (%) | 2 days ago88% | 2 days ago38% |
TrendMonth ODDS (%) | 2 days ago78% | 2 days ago47% |
Advances ODDS (%) | 8 days ago79% | 28 days ago49% |
Declines ODDS (%) | 10 days ago90% | 3 days ago73% |
BollingerBands ODDS (%) | 2 days ago87% | 2 days ago36% |
Aroon ODDS (%) | 2 days ago83% | N/A |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
AWEIX | 31.22 | N/A | N/A |
CIBC Atlas Disciplined Equity Instl | |||
TBCUX | 16.78 | N/A | N/A |
Tweedy, Browne Intl Val II - Ccy UnH | |||
JFCAX | 35.49 | N/A | N/A |
JHancock Fundamental All Cap Core A | |||
RYDAX | 99.93 | N/A | N/A |
Rydex Dow Jones Industrial Average® A | |||
VPRAX | 29.46 | N/A | N/A |
VY® T. Rowe Price Capital Apprec R6 |
A.I.dvisor indicates that over the last year, QSI has been loosely correlated with AXON. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if QSI jumps, then AXON could also see price increases.
Ticker / NAME | Correlation To QSI | 1D Price Change % | ||
---|---|---|---|---|
QSI | 100% | +4.17% | ||
AXON - QSI | 49% Loosely correlated | -0.87% | ||
VCYT - QSI | 47% Loosely correlated | +0.22% | ||
MESO - QSI | 39% Loosely correlated | -0.68% | ||
ARRY - QSI | 39% Loosely correlated | +1.48% | ||
VOR - QSI | 36% Loosely correlated | +3.78% | ||
More |
A.I.dvisor tells us that SLXN and QSI have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SLXN and QSI's prices will move in lockstep.
Ticker / NAME | Correlation To SLXN | 1D Price Change % | ||
---|---|---|---|---|
SLXN | 100% | +1.77% | ||
QSI - SLXN | 25% Poorly correlated | +4.17% | ||
CHRS - SLXN | 24% Poorly correlated | +1.27% | ||
FBRX - SLXN | 22% Poorly correlated | +0.53% | ||
ORIC - SLXN | 20% Poorly correlated | +2.10% | ||
MTVA - SLXN | 13% Poorly correlated | +1.16% | ||
More |